<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
<channel>
	<title>BioToday.com [新着ニュース]</title>
	<description>BioToday.comは医学情報、バイオテクノロジー、バイオベンチャー関連ニュースのデータベースです。</description>
	<link>http://www.biotoday.com/news.cfm</link>
	<managingEditor>biotoday@biotoday.com</managingEditor>
	<copyright>Copyright &#169; 2026 BioToday Ltd. All Rights Reserved.</copyright>
	<lastBuildDate>Wed, 12 Aug 2026 16:34:41 +0900</lastBuildDate>
	<language>ja</language>
	<docs>http://blogs.law.harvard.edu/tech/rss</docs>
	<item>
		<title>[医学] 動脈硬化疾患でもある2型糖尿病患者の心血管一大事がtirzepatide使用で減る</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110432&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110432&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / BMJ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 12 Aug 2026 16:34:40 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110432&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] ロフルミラストに比べてアジスロマイシンは慢性閉塞性肺疾患の悪化をより防ぐ</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110431&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110431&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / BMJ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 12 Aug 2026 16:13:14 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110431&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 腎移植患者の重度大腸菌感染にCRISPRの術を備えたファージが有効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110430&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110430&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 12 Aug 2026 12:49:26 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110430&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 睡眠不足で走り方が変わる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110429&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110429&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 12 Aug 2026 09:53:13 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110429&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] インドZydusの米国子会社がMereo社の肺疾患薬米国販売を担当する選択権利取得</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110428&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110428&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / ライセンス</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 12 Aug 2026 08:52:12 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110428&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 筋ジストロフィー薬を大詰め臨床試験に進めるEpicrispr社が9000万ドル調達 </title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110427&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110427&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 12 Aug 2026 07:57:03 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110427&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Infinimmune社がアトピー性皮膚炎治療抗体2つの開発資金7500万ドル調達</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110426&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110426&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 12 Aug 2026 07:06:45 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110426&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Vaderis社が末梢血管拡張症薬engasertibのPh3試験資金1億5200万ドル調達</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110425&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110425&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 12 Aug 2026 06:34:03 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110425&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] ホルモン感受性前立腺癌にNovartisの放射性薬Pluvictoが効いたPh3試験論文報告</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110424&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110424&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 11 Aug 2026 16:23:42 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110424&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Sionna社の嚢胞性線維症薬SION-719がPh2a試験で目ぼしい効果示さず</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110423&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110423&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 11 Aug 2026 16:02:15 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110423&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Jazz社がActio社を買ってPh1b/2a試験段階のてんかん薬ABS-1230を手にする</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110422&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110422&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 11 Aug 2026 14:37:44 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110422&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Tenax社の経口レボシメンダンTNX-103の心不全Ph3試験目標達成ならず</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110421&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110421&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 11 Aug 2026 13:59:54 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110421&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Novo社がアマゾンのAWSと組んで英国ロンドンにAI頼りの創薬拠点を築く</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110420&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110420&amp;ref=rss</guid>
		<category>技術 / 情報技術（IT） / 全般 || ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 11 Aug 2026 13:01:59 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110420&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Innate社がSobiの協力を得て皮膚T細胞リンパ腫（CTCL）薬のPh3試験を始める</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110419&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110419&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験 || ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 11 Aug 2026 12:14:11 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110419&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Silence社のRNA干渉薬divesiranの真性多血症Ph2試験目標達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110418&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110418&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 11 Aug 2026 09:53:18 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110418&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] MoonLake社のIL-17A/F阻害薬の乾癬性関節炎Ph3試験16週時点目標達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110417&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110417&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 11 Aug 2026 09:31:09 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110417&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] AbCellera社の抗NK3R抗体で1日の中等〜重度ホットフラッシュ回数が83%低下</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110416&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110416&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 11 Aug 2026 08:09:41 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110416&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 神経内分泌腫瘍を治療するITM社の放射性薬ITM-11を米国FDAが承認せず</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110415&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110415&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 完全回答（Complete Response Letter）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 11 Aug 2026 06:57:33 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110415&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Inozyme買収で手に入れたくる病薬をPh3試験不振を受けてBioMarinが切り捨て</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110414&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110414&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 中止</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 10 Aug 2026 16:41:30 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110414&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] BioVie社がパーキンソン病薬bezisterimのPh2試験のサブグループ解析結果を披露</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110412&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110412&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 10 Aug 2026 16:06:25 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110412&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 不活化細菌で太っている成人の体重減少</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110413&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110413&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 10 Aug 2026 10:03:21 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110413&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Vistagen社の社交不安症薬fasedienolの2回点鼻も有意効果なし</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110411&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110411&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 08 Aug 2026 07:50:01 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110411&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 嚢胞性線維症によるのではない気管支拡張症薬のPh2試験をSanofiが停止</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110410&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110410&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 08 Aug 2026 07:18:03 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110410&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Replimuneの黒色腫薬Tudriqevを米国がとうとう承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110409&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110409&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 07 Aug 2026 17:01:55 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110409&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Tarsus社がAlkeus社を買ってPh3試験段階のシュタルガルト病薬を手にする</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110408&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110408&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 07 Aug 2026 16:46:36 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110408&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] C. difficile感染を防ぐ細菌詰め合わせのPh3試験資金6000万ドルをVedantaが調達</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110407&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110407&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 07 Aug 2026 16:12:13 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110407&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] LifeMind社が移植臓器拒絶予防薬LIFE-001のPh2試験資金2億6400万ドル調達</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110406&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110406&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 07 Aug 2026 15:57:07 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110406&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Actimedが悪液質薬S-oxprenololの全権利を再び手にする</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110405&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110405&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / ライセンス</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 07 Aug 2026 15:37:18 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110405&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Modernaの季節性インフルエンザワクチンmFLUSIVAを米国FDAが承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110404&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110404&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 07 Aug 2026 15:16:56 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110404&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] IDH阻害薬を経たIDH変異神経膠腫に化学放射線療法がより効く</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110403&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110403&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 07 Aug 2026 13:27:51 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110403&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] バクテロイデス細菌による胆汁酸塩代謝亢進が食物アレルギーを抑制するらしい</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110402&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110402&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 07 Aug 2026 12:40:08 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110402&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] JAK阻害薬で移植肝臓の拒絶を解消しうる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110401&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110401&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 07 Aug 2026 10:15:53 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110401&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 切除する脳腫瘍の在処を知らせ、取り零し癌細胞を死なす蛍光ナノザイムを開発</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110400&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110400&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 07 Aug 2026 09:33:23 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110400&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 肩腱板損傷を悪化させる脂肪生成を線維脂肪生成前駆細胞（FAP）のDLK1が防ぐ</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110399&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110399&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 07 Aug 2026 07:40:32 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110399&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] V2a介在神経が豊富な脊髄介在神経の移植が脊髄損傷ラットに有効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110398&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110398&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 07 Aug 2026 06:58:08 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110398&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 好中球を呼び出すガレクチン3の阻止抗体で網膜の病的血管新生を抑制しうる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110397&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110397&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 06 Aug 2026 16:14:47 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110397&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 新型コロナウイルス感染入院患者の半数近くにウイルス再活性化が見られた</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110396&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110396&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 06 Aug 2026 12:14:30 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110396&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 良好な代謝と関連するFNIP1遺伝子変化を同定</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110395&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110395&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 06 Aug 2026 10:24:26 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110395&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 成長板が傷んだ後の病的骨形成を感覚神経の阻害薬ブピバカインで防ぎうる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110394&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110394&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 06 Aug 2026 09:51:40 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110394&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Mironid社が多発性嚢胞腎薬の開発資金4600万ドル調達</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110393&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110393&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 06 Aug 2026 08:37:56 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110393&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] AstraZenecaとBristol Myers Squibbの交渉はないとReutersが報じた</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110392&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110392&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 06 Aug 2026 07:54:00 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110392&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Schrodinger社の人工知能(AI)科学者BunsenをBristol Myers Squibbが研究所で採用</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110391&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110391&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 06 Aug 2026 07:18:20 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110391&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 武田薬品のナルコレプシー薬Orzeyfulを米国承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110390&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110390&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 06 Aug 2026 06:44:16 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110390&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] NovoのCagriSemaが2型糖尿病Ph3試験の血糖値比較でLillyのtirzepatideに及ばず</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110389&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110389&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 05 Aug 2026 16:28:47 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110389&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] PfizerのMetseraゆかりの経口GLP-1薬MET-224oも脱落</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110388&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110388&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 中止</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 05 Aug 2026 15:28:28 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110388&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] ImmunoBrain社の抗PD-L1抗体を無難に初期アルツハイマー患者に投与できた</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110387&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110387&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 05 Aug 2026 14:18:00 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110387&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] ナマズの癌の伝染を発見</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110386&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110386&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 05 Aug 2026 12:39:36 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110386&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Jazz社がZepzelcaの小細胞肺癌二番手治療用途取り下げ</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110385&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110385&amp;ref=rss</guid>
		<category>ビジネス / 会社運営 / 販売中止</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 05 Aug 2026 10:31:50 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110385&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Pathos AIがAlphamab、AstraZenecaとの取り引きで乳癌薬の扱いを拡大</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110384&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110384&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / ライセンス</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 05 Aug 2026 10:12:32 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110384&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Merck &amp; Coの抗TL1A抗体のPh2試験2つの1つが成功してもう1つが失敗</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110383&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110383&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 05 Aug 2026 09:47:25 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110383&amp;ref=rss</comments>
	</item>
</channel>
</rss>
